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ABSTRACT
Introduction: Within an International Atomic Energy Agency (IAEA) co-ordinated research project
(CRP), a remote end-to-end dosimetric quality audit for intensity modulated radiation therapy (IMRT)/
volumetric arc therapy (VMAT) was developed to verify the radiotherapy chain including imaging,
treatment planning and dose delivery. The methodology as well as the results obtained in a multi-
centre pilot study and national trial runs conducted in close cooperation with dosimetry audit net-
works (DANs) of IAEA Member States are presented.
Material and methods: A solid polystyrene phantom containing a dosimetry insert with an irregular
solid water planning target volume (PTV) and organ at risk (OAR) was designed for this audit. The
insert can be preloaded with radiochromic film and four thermoluminescent dosimeters (TLDs). For
the audit, radiotherapy centres were asked to scan the phantom, contour the structures, create an
IMRT/VMAT treatment plan and irradiate the phantom. The dose prescription was to deliver 4Gy to
the PTV in two fractions and to limit the OAR dose to a maximum of 2.8Gy. The TLD measured doses
and film measured dose distributions were compared with the TPS calculations.
Results: Sixteen hospitals from 13 countries and 64 hospitals from 6 countries participated in the mul-
ticenter pilot study and in the national runs, respectively. The TLD results for the PTV were all within
±5% acceptance limit for the multicentre pilot study, whereas for national runs, 17 participants failed
to meet this criterion. All measured doses in the OAR were below the treatment planning constraint.
The film analysis identified seven plans in national runs below the 90% passing rate gamma criteria.
Conclusion: The results proved that the methodology of the IMRT/VMAT dosimetric end-to-end audit
was feasible for its intended purpose, i.e., the phantom design and materials were suitable; the phan-
tom was easy to use and it was robust enough for shipment. Most importantly the audit methodology
was capable of identifying suboptimal IMRT/VMAT delivery.
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Introduction
Since 1995, the International Atomic Energy Agency (IAEA)
has conducted a series of co-ordinated research projects
(CRPs) with the purpose of supporting its Member States to
establish national audit activities through the development
of audit methodologies and guidelines on how to structure
and operate national dosimetry audit networks (DANs) [1–4].
In addition the IAEA, DAN database [5] was established to
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monitor audit activities; moreover, it provides information on
the coverage and operations of DANs in radiotherapy. The
collected data suggest that the demand for audits signifi-
cantly exceeds current capabilities [6].
It is generally agreed that complex radiotherapy techniques
like intensity modulated radiation therapy (IMRT) including
volumetric arc therapy (VMAT) need rigorous dose delivery
verification procedures. Dedicated quality assurance is
required during the radiotherapy units and treatment plan-
ning systems (TPS) commissioning, when IMRT/VMAT is intro-
duced in clinics and finally as part of patient specific
validation of the dose delivery [7–9]. To gain confidence that
these complex treatments are accurately applied to patients,
an independent verification, or a dosimetry audit, of the treat-
ment chain should be performed [7,10]. The increased clinical
use of IMRT and VMAT in IAEA Member States further sup-
ports the need for dosimetric audits of these treatment tech-
niques for accuracy of dose delivery and safety purposes.
There are examples of IMRT verification projects [9,11–15]
and several examples of pre-treatment QA performed at hospi-
tals described in the literature [11,16–18]. These audit proce-
dures include dosimetry ranging from point dose
measurements, to 2D dosimetry with films and/or dosimeter
arrays to 3D dosimetry with dosimeter arrays or gel. Even
though IMRT verification is often implemented locally in a hos-
pital there are studies demonstrating that local QA results do
not necessarily concur with independent audit results [19,20].
The common approach for evaluating dose distributions is the
use of a gamma analysis, which in some cases has shown
inconsistencies between the results performed with the local
QA equipment and from independent audits, which normally
yields lower passing rates [19–23]. The inconsistencies noted
above between local and independent audit QA results support
the need for an independent dosimetry audit (beyond just rely-
ing on local QA measurements) for consistent, accurate and
safe radiation therapy treatments utilizing complex modalities.
The purpose of this work is to present both the method-
ology of a new remote end-to-end audit for IMRT/VMAT head
treatment delivery and the results obtained in a comprehen-
sive testing phase. This audit aims to provide an independent
verification of the radiotherapy chain including imaging, dose
calculation, set-up and dose delivery, representing a continu-
ation of previously developed audit methodologies [3,4,24,25].
This remote end-to-end audit methodology was developed
under an IAEA CRP and included a multicentre pilot study and
national trial runs conducted by various DANs in close cooper-
ation with the IAEA.
A methodology for on-site IMRT head and neck audits,
which is currently under implementation at the national
level, was also recently developed by IAEA [26,27]. The
advantage of an on-site audits is that any inconsistencies
found can be immediately tracked to the cause. In a remote
end-to-end test, error analysis is more challenging and if
major deviations persist, an on-site visit is recommended. On
the other hand, if an audit is to be performed on a large
scale, remote audit is the modality of choice.
Material and methods
IMRT/VMAT phantom
A solid phantom specifically designed for this audit (Figure
1(a)) has dimensions of 15 15 15 cm3 and contains an
insert (denoted as IMRT QA insert) of 6.35 6.35 6 cm3
outer dimensions. It contains an imageable planning target
volume (PTV) and organ at risk (OAR) embedded into it. The
distance between the PTV and OAR is 8mm (Figure 1(b)). The
phantom is made of polystyrene (density of 1.040 g/cm3) while
the PTV and OAR structures are made of Solid Water HE
(GAMMEX RMI, Middleton, WI, USA) (density of 1.032 g/cm3).
For accurate positioning during CT scanning/imaging and dur-
ing set-up on the treatment couch, the outer surface of the
Figure 1 The IMRT polystyrene solid slab phantom with the IMRT QA insert disassembled and showing the location of PTV_I_TLD, OAR_I_TLD and EBT 3 film (a)
and a cross section of the IMRT QA insert showing the TLD locations in the PTV and OAR (b).
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phantom is engraved with crosses and markings for appropri-
ate alignment.
The IMRT QA insert can be loaded with EBT3 Gafchromic
film in the mid-trans axial plane along with four thermo-
luminescent dosimeters (TLDs), which are labeled as
PTV_S_TLD and PTV_I_TLD for the superior and inferior posi-
tions in the PTV, respectively, and OAR_S_TLD and
OAR_I_TLD for the superior and inferior positions in the OAR,
respectively. Extra plugs and inserts enable additional meas-
urements with a small volume ionization chamber (IC) (PTW
Semiflex 31010, PTW PinPoint 31006 and Exradin A1SL) in
the position of each TLD.
Imaging dose assessment
The imaging dose during CT scanning and its potential
impact on the final audit dosimetric results was given a spe-
cial focus in this study, since the contribution of CT dose to
the OAR doses was expected to not be negligible. Therefore,
the CT doses at the location of the OAR TLDs were deter-
mined for CT scans performed with different scanners and
scanning parameters/protocols as used in several clinics.
More specifically, for each CT scan evaluation four TLDs were
positioned in the IMRT QA insert and two external TLDs
were attached on the phantom surface (mid-lateral phantom
sides); the locations of six TLDs are shown in Figure 1(a). The
contribution of imaging doses to the PTV and OAR IMRT
doses was derived from two outside TLDs attached to the
phantom surface during CT scanning (Figure 1) and removed
for IMRT irradiations. For this purpose, the phantom was
filled with TLDs located in the PTV, OAR and outside (Figure
1) and CT scanned. The ratio of the signals from the inside
TLDs to the signals from the outside TLDs was determined
for a range of CT scanners and scanning parameters/proto-
cols. The signal measured from the outside TLDs corrected
for the inside/outside CT dose ratio was subtracted from the
overall signal of TLDs at PTV and OAR.
A relation between CT dose index (CTDI) values and
measured external TLD signal was investigated, to develop a
method for estimating the imaging dose in order to subtract
it from the dose received by inside TLDs during IMRT
dose delivery.
End-to-end test methodology
The audit exercise begins with the local centre being
instructed to perform a CT scan of the phantom using their
clinical protocol for IMRT head (or head and neck) treat-
ments. Next, the CT images are transferred to the TPS and
an IMRT treatment plan is generated using the pre-defined
dose prescriptions and dose constraints provided in the audit
instructions. For the treatment plan preparation, the aim is
to deliver 4 Gy in two fractions to the PTV, while limiting the
dose to the OAR to below 2.8 Gy. The dose constraints per
fraction are as follows: D95%¼2.0 Gy and V93%<1%,
Dmax<2.2 Gy (anywhere in the plan) and Dmax<1.4 Gy in OAR.
The treatment plan is to be verified using the local patient-
related QA procedures and then the phantom irradiations
are to be performed with two fractions delivered one by one
without the phantom repositioning.
A set of instruction sheets for this end-to-end audit, data
sheets for reporting the details of irradiation, additional
instructions for DANs on how to handle and evaluate the
dosimeters, and the final format of the reporting of results
were also developed.
Dosimetric evaluation
For the multicentre pilot study, the dosimeters were pre-
pared and analyzed by the IAEA Dosimetry Laboratory (DOL).
As mentioned above, two dosimeter types were used for the
measurements within the phantom, i.e., TLD-100 (Harshaw,
WI, USA) and Gafchromic EBT3 film (Ashland, OR, USA), one
for determining the point doses and one for verifying the
dose distribution, respectively.
For TLD, approximately 165mg of LiF powder was encap-
sulated in plastic capsules (2.8 cm length, 0.5 cm diameter).
TLD powder from the capsules was read/analyzed with a
PCL3 TLD reader (Fimel, France) following the established
IAEA protocol [28]. The uncertainty in the TLD measurements
was 1.6% (1 standard deviation (SD)).
The scanning of the irradiated EBT3 films was performed
with an EPSON 11000XL flat-bed scanner (EPSON, Nagano,
Japan) using the transmission mode, 150 dpi resolution and
48-bit RGB color scale. The calibration films were irradiated
with seven doses in the range from 0.5 to 6Gy. The calibra-
tion films were irradiated within 2 weeks of a phantom’s
audit irradiation. The calibration curve and the dose distribu-
tions from the films were obtained using FilmQA Pro
(Ashland, OR, USA) software with the triple channel method
[29]. Gamma evaluation was performed for dose distributions
matched using pin registration marks on the film and nor-
malized to the same dose at the isocentre. The region of
interest (ROI) was selected to include the whole PTV and
OAR and exclude the pin marks on the film. The gamma ana-
lysis evaluation parameters were: 3% dose difference, 3mm
distance-to-agreement, 20% dose threshold, global gamma.
Multicentre pilot study
Participants from Austria, Belgium, Finland, Sweden, UK and
USA (who were all closely involved in the methodology
development) together with seven DANs from Brazil, China,
Cuba, Czech Republic, India, Poland and Thailand took part
in the multicentre pilot study. DANs work in close cooper-
ation with local hospitals to perform all tests in a clinical
environment. Each of the pilot study participants was pro-
vided with an audit set consisting of a phantom preloaded
with dosimeters, instructions and datasheets. They were
instructed to ‘treat’ this IMRT phantom as if it were one of
their patients so that the entire IMRT treatment preparation
and delivery process from end-to-end was carried out in
accordance with their clinical process.
After the phantom irradiation was completed, the dosime-
ters (TLDs and film) were returned to the IAEA dosimetry
laboratory for read-out, evaluation and analysis. Participants
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were requested to report, among other things, the TPS doses
calculated at the positions of each of the four TLDs as well
as to provide the DICOM file with the TPS dose distribution.
In total 16 hospitals from 13 countries participated in the
multicentre study; details of the equipment used are avail-
able in Supplementary Table S1.
In addition to the audit procedure of measuring the deliv-
ered doses with TLDs, IC measurements were also performed
during the multicentre pilot study to verify whether any add-
itional corrections were needed when using TLDs in the
IMRT phantom. Furthermore, small isocentre shifts of 1mm
were simulated in the TPS to assess how potential phantom
setup errors might affect the audit results. Five project partic-
ipants performed these additional calculations for the phan-
tom shifted laterally, and in vertical directions.
National trial runs
After the completion of the multicentre pilot study, the audit
methodology was tested at the national level by DANs. The
phantoms which each DAN has received during the pilot
study were used for a circulation within the national runs.
The same methodology description together with instruc-
tions were provided to DANs to initiate their national trial
runs. They were performed in six countries (Brazil, China,
Cuba, Czech Republic, India, Poland) where in total 64 hospi-
tals received the phantom for irradiation (details of equip-
ment used is available in Supplementary Table S2). Each
DAN organizing a trial in the country was responsible for
providing the dosimeters and performing the audit evalu-
ation and analysis.
Methodology robustness
The one-sample Wilcoxon signed ranks test was used to
determine whether the median of the distribution of the
ratios of measured to hospital stated doses (Dmeas/Dstat)
calculated for the four TLD locations was different from 1.
This would indicate a bias and could reveal, besides the
problems with systematic errors related with beams calibra-
tion or equipment used, the need for an additional correc-
tion related to the phantom design. The choice of the test
was based on the analysis of normality (Shapiro–Wilk test)
and the analysis of Q-Q plots of the groups of Dmeas/Dstat
ratio results for the four TLD locations.
In addition, the non-parametric Kruskal–Wallis test, based
on median scores and ranks, was conducted to investigate
whether there was a significant difference between the
Dmeas/Dstat ratio data obtained in the multicentre pilot study
versus the national trial runs.
The impact of treatment technique and underlying equip-
ment was also reviewed.
Results
Imaging dose assessment
Evaluation of CT doses obtained from 11 scans of the phan-
tom, suggested that TLD signals resulting from CT imaging
were high enough to contribute to the overall TLD measured
doses. Imaging dose contributions amounted to up to 2.6%
of PTV dose and up to 20.6% of OAR dose.
The ratio of the signal from the inside to the outside TLDs
ranged between 1.07 and 1.21, with an average value of 1.13
across the different scanning protocols.
The relation between the measured TLD signal and CTDI
values can be seen in Figure 2. The results show some outly-
ing CTDI values, therefore it was decided that the external
TLD would be used to derive the TLD signal resulting from
the planning CT scan rather than CTDI values.
Multicentre pilot study
The submitted details of the treatment plans showed that
participants generally achieved the requested maximum
dose constraint, except for two cases where the maximum
dose for anywhere in the plan was above the 2.2 Gy limit
Figure 2. Relation between the TLD signal and the CTDI doses.
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(both reported 2.27Gy). The planned OAR doses were all
below 1.4 Gy per fraction. For different participants the mean
OAR doses ranged from 0.30 to 1.06 Gy per fraction.
Each treatment plan was verified using local procedures
based on detector arrays, such as MatriXX (IBA Dosimetry,
Schwarzenbruck, Germany), ArcCheck (Sun Nuclear
Corporation, Melbourne, Australia), Octavius (PTW, Freiburg,
Germany), Delta 4 (ScandiDos, Uppsala, Sweden) or EPID
(Varian, Palo Alto, CA, USA). All but one participant success-
fully passed local QA verification of their treatment plans.
The TLD results for the 16 participants who contributed to
the multicentre pilot study are shown in Figure 3(a). Three
participants repeated the irradiation. Participant #2 repeated
the irradiations due to a large discrepancy of doses in the
OAR caused by a steep dose gradient. A new TPS plan was
generated with the smaller gradient in the OAR volume, which
resulted in good agreement for the repeated irradiation.
Participant #5 made a mistake during the phantom irradiation
and even though after TPS recalculations the results were
acceptable the irradiation was repeated. Participant #10 had
the average dose in the PTV 6.6% higher than planned; the
follow-up irradiation with the same plan confirmed that the
irradiation was performed correctly, and the discrepancy origi-
nated in the TPS calculations. This participant was about to
introduce IMRT into clinical practice and thus was not suffi-
ciently experienced. Other participants (#11 and #15) with out-
lier results in OAR only, were not requested to repeat
irradiation and the reasons are discussed below.
The Dmeas/Dstat ratios were calculated for all four TLD loca-
tions; the average and the SD values are 0.998 ± 0.028,
0.993 ± 0.023, 1.010 ± 0.063 1.003 ± 0.047 for PTV_S, PTV_I,
OAR_S and OAR, respectively. The mean ratio of the TLD
measured doses in the PTV to the stated ones was within
±5% for all participants except Participant #10. The ±5%
acceptance limit was defined based on the SD of all Dmeas/
Dstat ratios in PTV. This limit corresponds to expanded SD of
5.1% (k¼ 2), giving approximately ±5% acceptance limit.
More variability was observed for the OAR results, with
the minimum ratio of Dmeas/Dstat as low as 0.82 and the max-
imum of 1.14 as shown in Figure 3(a). This was expected due
to high dose gradients across OAR which were also more
sensitive to phantom positioning uncertainties. All results
were below the 2.8 Gy planning constraint (Figure 3(b)). The
TPS simulation of the phantom isocentre shifts shown that
the doses calculated for the TLD powder volume can change
by 1.0% for PTV TLDs, while the 1mm shift could make a dif-
ference to up to 11.7% for OAR TLDs.
The comparison of doses measured in the PTV with the IC
and the TLD showed excellent agreement (average difference
between dosimeters 0.5%, SD ¼ 1.2%). The OAR IC dose
results showed larger scatter with the SD of 9.9%, greater
than that for TLD.
Gamma analysis of film evaluation resulted in very good
agreement of the analyzed dose distributions. An example of
the film measured and TPS calculated dose profiles can be
seen in Figure 4. The average result was 99.5% of points pass-
ing the gamma criteria with the minimum value of 96.7%.
Figure 3. TLD results for multicentre study and national trials; TLD locations marked as: PTV_S_TLD and PTV_I_TLD for the superior and inferior positions in the
PTV and OAR_S_TLD and OAR_I_TLD for the superior and inferior positions in the OAR. (a) ratio of the TLD measured to stated doses for each institution from the
multicentre study (the ±5% acceptance level applicable for PTV only is shown in red), data for institutions 2, 5 and 10 include the initial (1) and repeated (2) irradi-
ation results. (b) TLD dose measurement results in OAR for each institution from the multicentre study (the 2.8 Gy acceptance limit is shown in red), data for institu-
tions 2, 5 and 10 include the initial (1) and repeated (2) irradiation results. (c) ratio of the TLD measured to stated doses for each institution from the national trials
(the ±5% acceptance level applicable for PTV only is shown in red); (d) TLD dose measurement results in OAR for each institution from the national trial (the 2.8 Gy
acceptance limit is shown in red).
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National trial runs
The details of the treatment plans developed for national
audits identified three plans where the maximum dose any-
where in the plan was above the planning constraint limit and
five plans for which OAR exceeded the maximum dose limit (in
total seven different plans). All participants confirmed that
their plans passed the local QA verification procedure. The
measurements obtained from the national trial runs performed
in six countries with 64 participating hospitals are summarized
in Figure 3(c) and 3(d). The SD of the ratio of measured to
stated dose for all results can be found in Table 1.
In 47 of 64 cases the TLD results in the PTV were within the
5% acceptance limits. Most of the unsatisfactory results (15/17)
were observed in countries #5 and #6; for which the spread of
results was substantially higher than in other countries (see
Table 1). The doses measured in the OAR were all below the
2.8 Gy threshold, with a minimum measured dose of 0.88Gy
and a maximum of 2.43 Gy for all cases.
The gamma analysis results identified seven centres who
failed to achieve the 90% pass rate. One institution achieved
only 10% of pixels passing this gamma criterion. Three of
the EBT3 film results showed gamma passing rate below
50% but TLD results were within 5% limit. This suggests
issues with film handling at the national level rather than
dosimetric problems.
Some of centres with low gamma passing rates also had
poor TLD results, with two centres failing both TLD and
film criteria.
Figure 4. Comparison of measured and TPS calculated profiles; the IMRT QA insert with regions and cross-sections marked (a), vertical profile along the axis pass-
ing through the isocentre (A-A) (b), horizontal profile along the axis passing through the isocentre (B-B) (c) and a horizontal profile along the axis passing through
the OAR midpoint (C-C) (d).
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In total, 21 institutions (34%) failed the audit for either
one or both criteria. The follow-up on the poor results is still
ongoing at the national level and these results have not
been reported so far.
Methodology robustness
The Shapiro–Wilk test showed that Dmeas/Dstat ratios for dif-
ferent TLD locations in the phantom did not have the normal
distribution and therefore a non-parametric statistical test
was used. The one-sample Wilcoxon signed rank demon-
strated that the median Dmeas/Dstat ratios obtained in both
the multicentre pilot study and the national trial runs were
not different from 1 (p> .01) with the p values ranging from
0.02 to 0.9, i.e., no systematic difference was observed
between the stated dose and the measured one.
Furthermore, in both the multicentre study and the
national trial runs no significant difference was found
between the results related to different locations within the
phantom (with the p values of .05 for multicentre study and
.18 for national runs) as well as between the results of both
multicentre and national studies with p value of .63
(Mann–Whitney test, p> .01).
Additional tests did not detect any significant differences
in Dmeas/Dstat ratios between the linac manufacturers, deliv-
ery techniques or plans calculated on different calculation
grids (0.4–5mm). Even though the number of MU per 2Gy
fraction (302–1202MU) differed substantially between plans,
statistical tests did not detect any significant differences in
Dmeas/Dstat ratios.
Discussion
The remote end-to-end audit methodology described in this
work aims to independently verify the entire IMRT/VMAT
treatment chain, covering steps from imaging to dose
delivery. The imaging dose assessment conducted during the
initial phase of the CRP showed the importance of incorpo-
rating the CT imaging TLD measurements, i.e., imaging doses
were found to potentially influence the final TLD audit result
if not corrected. This is in agreement with the findings of
Molineu et al. [13] for a similar audit methodology, reporting
a CT dose contribution of approximately 1% to the PTV dose
of 6.6 Gy. Also, their attempt to use the CTDI values for esti-
mating the CT dose contribution to the PTV and OAR TLD
doses was not successful, similar to our results. The CT dose
vs. CTDI data scatter might be due to several reasons. First,
the CTDI and TLD dose relationship is complex because the
CT X-ray energy spectrum changes throughout the phantom
and impacts on the signal recorded by the TLD. Next, there
is a large impact on the TLD signal by the individual CT scan-
ner parameters. For example, a similar TLD signal of approxi-
mately 0.7 million counts was associated with either 13 mGy,
26 mGy or 77 mGy in CTDIs (see Figure 2) depending on the
CT scanner and protocol used. This largely depends on the
type of phantom used for the CTDI determination as both
head and body phantoms are in clinical use, resulting in very
different CTDIs and variations in CT manufacturers and mod-
els dose reporting method (generally up to ±20% disagree-
ment is allowed between the displayed CTDI value and
measurements). The most striking finding of this imaging
dose study was the unexpectedly wide range of CTDI values
reported by participants, starting from abaut 5 mGy with an
upper limit of approximately 78 mGy. This clearly indicates
the optimization and standardization potential for planning
CT in the head and head-and-neck regions to minimize
patient exposure in healthy tissue.
After the design and development of an IAEA audit, the
multicentre pilot study is a major milestone in the testing of
the new prototype phantom, verifying whether the planning
objectives and constraints can realistically be achieved within
the phantom geometry, and checking the feasibility of irradi-
ation conditions. Such a pilot study validates the remote
audit process, provides feedback on the developed docu-
ments (e.g., instructions and data sheets) and gives an indi-
cation of the workload involved for both the centres to be
audited and the DAN to provide the evaluation. Since the
pilot study results are used as the benchmark for national
audits, it is essential to include a representative number of
centres with respect to equipment and overall experience.
An extra effort is needed when participating in pilot studies
for audit methodologies; for example, extra robustness tests
such as the influence of positioning shifts on measurement
points are needed and assessing dosimetry analysis parame-
ters for radiochromic film. By doing so, the influence of posi-
tioning shifts was found to be very high in the OAR (up to
11.7% dose difference for a 1mm shift), which lead to devel-
oping the acceptance criteria for OAR that are not based on
Dmeas/Dstat ratios as was done for the PTV. Instead it was
decided to verify whether the planning constraints were ful-
filled. The high sensitivity of the measurement points in the
OAR to positioning also justifies the choice of orientation of
the EBT3 film in the transverse plane, allowing a close exam-
ination of the dose gradient in the OAR region.
Table 1. Average results of TLD measurements for all national trial runs.
TLD location
PTV_S PTV_I PTV OAR_S OAR_I OAR
Country 1 N ¼ 11
Dmeas/Dstat 1.007 1.006 1.006 0.992 1.003 0.997
SD 0.031 0.029 0.029 0.043 0.040 0.041
Country 2 N ¼ 5
Dmeas/Dstat 0.988 1.000 0.994 0.963 0.979 0.971
SD 0.012 0.023 0.018 0.028 0.028 0.028
Country 3 N ¼ 2
Dmeas/Dstat 0.980 0.971 0.976 0.993 1.000 0.996
SD 0.011 0.033 0.021 0.103 0.092 0.092
Country 4 N ¼ 3
Dmeas/Dstat 1.007 1.007 1.007 1.040 1.020 1.007
SD 0.015 0.032 0.023 0.046 0.061 0.023
Country 5 N ¼ 13
Dmeas/Dstat 0.970 0.974 0.972 0.998 0.968 0.983
SD 0.040 0.044 0.041 0.147 0.122 0.133
Country 6 N ¼ 30
Dmeas/Dstat 0.998 1.030 1.014 0.998 1.003 1.000
SD 0.048 0.056 0.054 0.090 0.088 0.088
All N ¼ 64
Dmeas/Dstat 0.993 1.009 1.001 0.996 0.995 0.995
SD 0.042 0.050 0.047 0.093 0.086 0.089
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Based on the results of the multicentre study, the accept-
ance limits of 5% for the dose measurements in PTV and
2.8 Gy dose threshold for the dose measurements in OAR
were considered feasible. For film gamma evaluation, the cri-
terion of 90% of points passing selected criteria was
adopted. These acceptance levels were recommended for
testing during the national trial runs.
Centres participating in the multicentre pilot, who were
experienced with IMRT/VMAT treatment planning and deliv-
ery, had very good audit results, while other centres who
were just beginning their clinical implementation of IMRT
did not do so well in this audit and benefited from participa-
tion in this study. As mentioned above, three participants
repeated the exercise and in all these cases the local IMRT
verification methods were passed with good results. The
finding that local QA methods do not always correlate with
the audit results has also been reported by others [19,20,30].
The results of the national trial runs indicated a much
greater percentage of centres not meeting the audit accept-
ance criteria than observed in the multicentre study results,
i.e., the SD of the Dmeas/Dstat ratio was much larger. On the
other hand, the audit implementation at the national level
was done correctly by the respective DANs as the median
results for the multicentre and national trial are similar.
However, there were challenges with film handling in
one country.
The follow-up of the unsatisfactory results includes at the
first place verification whether all instructions were followed.
Auditors request the participants to send additional informa-
tion which is reviewed and the audit is repeated. The infor-
mation on the linac output check (ionization chamber and
electrometer details, calibration certificate, factors and correc-
tions used), MLC performance (positioning accuracy test
results) and the details of the TPS parameters related to the
small fields and MLC (small fields output factors and profiles,
detectors and corrections used, leaf gap and transmission)
are requested. All of the parameters mentioned above could
be a reason for deviations detected during the audit and
should be carefully verified by a clinical medical physicist
from the audit team.
Even though the IMRT/VMAT end-to-end audit presented
in this work is based on a rather simple phantom which
allows a dose distribution evaluation in a single plane only,
it is able to detect shortcomings in the implementation of
IMRT/VMAT. A phantom with a small PTV and OAR is espe-
cially challenging. The analyzed dose distributions using
EBT3 film were relative and normalized to PTV. Therefore,
any potential linac output problems cannot be detected by
film measurements but by TLD only. In contrast, any prob-
lems with MLC characteristics, phantom positioning shifts or
increased uncertainty in isocentre positioning and any other
geometry inaccuracies, can be detected using the film [31].
The analysis of results obtained for this end-to-end audit
did not detect any significant influence of linac type and
manufacturer, delivery technique, number of monitor units
and TPS calculation grid size. Nakamura et al. also did not
detect any dependence on the delivery technique [32]. On
the other hand, in other studies differences were found
between TPS models, specifically when beam models were
provided by the vendor [11,12,33]. Also, the treatment tech-
niques or infrastructure of the department (number of med-
ical physicists or age of equipment) have been shown to
affect the results [12].
The overall aim when designing this IMRT/VMAT audit
was to develop an end-to-end test that could be adopted at
the national level by a DAN having a certain expertise gained
during the implementation of the previous CRP’s. The multi-
centre pilot study and the national runs proved that the
IMRT/VMAT dosimetric end-to-end audit methodology can
be implemented without major challenges. The phantom
design and materials used proved to be suitable for the pur-
pose; the phantom was easy to use and there were no issues
during the shipment. More importantly, this audit is capable
of identifying suboptimal IMRT/VMAT delivery in a radiother-
apy department.
Development of such a remote audit is in line with rec-
ommendations [7] that regular independent peer review dos-
imetry audits should be made available to radiotherapy
centres and that they are especially important when new
treatment units are installed or when introducing new treat-
ment techniques and/or TPS software updates.
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